Analysts Issue Forecasts for ELVN Q2 Earnings

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Analysts at Lifesci Capital issued their Q2 2025 earnings estimates for Enliven Therapeutics in a research note issued to investors on Thursday, May 29th. Lifesci Capital analyst S. Slutsky expects that the company will earn ($0.54) per share for the quarter. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share. Lifesci Capital also issued estimates for Enliven Therapeutics’ Q3 2025 earnings at ($0.57) EPS and Q4 2025 earnings at ($0.58) EPS.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06).

Other research analysts have also issued research reports about the company. Jones Trading dropped their target price on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, May 16th. HC Wainwright lifted their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 15th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $37.25.

Enliven Therapeutics Trading Up 0.6%

Enliven Therapeutics stock opened at $17.84 on Friday. Enliven Therapeutics has a twelve month low of $13.30 and a twelve month high of $30.03. The stock has a 50 day moving average of $18.01 and a two-hundred day moving average of $20.96. The stock has a market capitalization of $875.39 million, a price-to-earnings ratio of -9.39 and a beta of 1.07.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the business’s stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total transaction of $69,322.50. Following the transaction, the chief financial officer now owns 23,000 shares in the company, valued at approximately $490,590. The trade was a 12.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Anish Patel sold 6,667 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $21.44, for a total value of $142,940.48. Following the transaction, the chief operating officer now directly owns 323,310 shares of the company’s stock, valued at approximately $6,931,766.40. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,111 shares of company stock worth $1,643,398 over the last 90 days. Company insiders own 29.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after purchasing an additional 1,114 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Enliven Therapeutics by 3,058.1% in the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock valued at $53,000 after purchasing an additional 2,630 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at about $60,000. KLP Kapitalforvaltning AS purchased a new stake in Enliven Therapeutics during the fourth quarter worth about $97,000. Finally, BNP Paribas Financial Markets acquired a new position in Enliven Therapeutics during the fourth quarter worth about $112,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.